Parexel introduces FSP outsourcing model at DIA

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/shirnosov)
(Image: Getty/shirnosov)
Parexel launched a delivery model for its FSP services at DIA 2019 Global Annual Meeting in San Diego as the company aims to tailor solutions for biopharma customers.

The solutions provider announced its new outsourcing delivery model for Functional Service Provider (FSP) services to focus on patient centricity in its customer solutions. Parexel has been providing FSP services for a number of years and is now integrating its offerings with this model to provide a multifunctional resource.

Chris Baker, SVP and global head of FSP at Parexel told us,“Today’s biopharma companies are keeping the patient perspective and patient needs as the main focus is essential throughout the drug development process and improve outcomes, but they require access to the right expertise and functional services to accomplish this.”

Parexel views the launch of this model as a means of aligning the company with the changing needs of its biopharma customers looking for full service, functional, or hybrid approaches.

“Today’s drug development landscape is constantly changing, and with that, so are the needs of biopharma companies. Today’s biopharma companies need flexible and hybrid approaches to their outsourcing needs,”​ said Baker.

Through this delivery model,​ customers will have access to multifunctional resources through a single point of contact.

Parexel FSP includes more than 5,000 specialized employees worldwide with a 95% success rate in delivering repeat business.

The company’s functional service solutions include global clinical operations, global data operations, pharmacovigilance, medical affairs, medical writing, and regulatory support. The company has provided FSP in both full service and flexible clinical development services through more than 1400 projects.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Related suppliers

Follow us

Products

View more

Webinars